Please note that due to the adverse weather conditions phone contact to the SPIRIT office is limited.
Last modified: Thu, 01 Mar 2018 09:41:41 GMT
Key information on data entry and responding to queries as we approach the end of the trial.
Last modified: Wed, 24 Jan 2018 09:50:32 GMT
Further information on the end of trial procedures including SAEs and IMP transition
Last modified: Wed, 24 Jan 2018 09:56:01 GMT
Information on the end of trial transition of dasatanib to commercial stock and destruction requirements.
Last modified: Wed, 06 Dec 2017 16:01:45 GMT
Important reminder for SAE reporting
Last modified: Thu, 08 Jun 2017 09:54:31 BST
Substantial Amendment 50 Guidance PDF 125Kb
Substantial Amendment 50 Guidance
SAE Completion Guidelines v2.0 PDF 72Kb
Please find attached detailed SAE reporting guidelines for sites
ASH 2015 - Prof O'Brien's Update PDF 2,098Kb
Prof Steve O'Brien's report from the 57th ASH annual meeting
SPIRIT 2 Presentation slide - BSH 2015 PDF 894Kb
Prof Steve O'Brien slides from BSH 2015
ASH 2014 - Prof O'Brien's update PDF 934Kb
Professor Steve O’Brien’s report from the 56th ASH Annual Meeting
The update on the SPIRIT trials was given, see attached